CMRA COMERA LIFE SCIENCES HOLDINGS INC

Comera Life Sciences to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

Comera Life Sciences to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it will be participating in the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1, 2022 at the New York Athletic Club in New York.

Interested parties can access a copy of Comera’s current investor presentation at:

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms that can be self-administered. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.

To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit .

Contacts:

Comera Investor

John Woolford

ICR Westwicke

  

Comera Press

Jon Yu

ICR Westwicke



EN
17/11/2022

Underlying

CMRACOMERA LIFE SCIENCES HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMERA LIFE SCIENCES HOLDINGS INC

 PRESS RELEASE
Free
CMRA COMERA LIFE SCI...

Comera Life Sciences Announces Bridge Financing and Exercise of Take P...

Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Com...

January 4, 2024 1 EN
 PRESS RELEASE
Free
CMRA COMERA LIFE SCI...

Comera Life Sciences Announces Process Exploring Strategic Alternative...

Comera Life Sciences Announces Process Exploring Strategic Alternatives WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic tr...

December 6, 2023 1 EN
 PRESS RELEASE
Free
CMRA COMERA LIFE SCI...

Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

Comera Life Sciences Appoints Dorothy Clarke to Board of Directors WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. “Dorothy’s extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines,” said Jeffrey Hackman, Chairman and Chief Executive Officer...

November 13, 2023 1 EN
 PRESS RELEASE
Free
CMRA COMERA LIFE SCI...

Comera Life Sciences Reports Financial Results for Third Quarter 2023 ...

Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights – Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera’s global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – –   Completed previously announced $4.1 million private placement of shares of Comera’s common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN,...

November 9, 2023 1 EN
 PRESS RELEASE
Free
CMRA COMERA LIFE SCI...

Comera Life Sciences Presents SQore™ Platform Technology Data at PODD:...

Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- (), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera, will present data from Comera’s SQore platform which is designe...

October 16, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch